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(GSFQ) is a speciﬁc Quality of Life (QoL) instrument which
measures the impact of GERD symptoms on QoL. This study
aims to adapt the GSFQ into Spanish (for Spain) culture and
check the questionnaire psychometric properties. METHODS:
An expert panel composed by a gastroenterologist, two method-
ologists, one expert in clinical research and one pharmacoecono-
mist supervised the adaptation process. The original instrument
was translated and back-translated by two independent transla-
tors. For psychometric measures, a small sample was used to
check the initial comprehension and factibility. A national rep-
resentative sample was selected, stratiﬁed by gender, age (<45,
45 years) and GERD severity (0-I, II, Savary-Miller score).
Content validity was ensured by the original instrument. Cron-
bach’s Alfa was used to assess reliability, and exploratory factor
analysis to assess dimensionality. The EuroQol questionnaire and
corresponding Visual analogue scales (VAS) were used for con-
current validity. RESULTS: A total of 3997 patients with pyrosis
symptoms were recruited by 490 clinicians. Mean age was 49.35
(14.35) years and 48.4% were women. No ceiling or ﬂoor effects
were detected in item responses. The reliability was good (0.864)
and only 1 dimension exhibited an eigenvalue (3.45) above 1,
explaining 58% of available variability. All items loaded on
this dimension. Correlation were moderate but signiﬁcant
(p < 0.001) with EuroQol (0.499) and VAS (-0.481). The
average score was 34.17 (19.685), in the 0–100 scale. Mean
scores were signiﬁcantly different between GERD diagnosed
severity levels (F4,33035 = 84.9, p < 0.005), but no differences were
found between Savary-Miller level IV and levels II-III. CON-
CLUSION: The Spanish version of the GSFQ has good psycho-
metric properties, behaves as a unidimensional scale, and is
capable to discriminate between patients with varying degrees of
GERD severity.
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OBJECTIVES: According to recently published guidelines,
treatments effects on patient’s health status should be measured
by validated disease-speciﬁc Patient Reported Outcomes con-
cepts. The aim of this study is to develop and validate a PRO
questionnaire based on a conceptual framework for Crohn’s
disease. METHODS: An item pool of 77 items was generated
through in focus groups and validated in a German sample
(n = 104). Other data included the SF-36 and IBDQ. RESULTS:
A principal component analysis revealed 7 independent factors:
impact, intimacy, abdominal pain, bowel movements, nausea,
extraintestinal problems and night sweat. The impact factor
was shown to comprise further three interpretable domains:
emotional, social, and physical. CONCLUSION: Symptoms
and consequences of Crohn’s disease need to be measured sepa-
rately, since their constituent items do not load on the same
factors. Further investigation could reduce the amount of items
of one concept or ﬁnd further items for relevant aspects such as
problems with intimacy.
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OBJECTIVES: To quantify the effects of chronic constipation on
health-related quality of life, work productivity, and activity
impairment. METHODS: Data are taken from the 2005 U.S.
National Health and Wellness Survey, an annual cross-sectional
study of the health care attitudes and behaviors of adults (age
18+). Chronic constipation sufferers are deﬁned as experiencing
chronic constipation in the past twelve months, and non-sufferers
have not experienced chronic constipation. Respondents who
experience inﬂammatory bowel disease or irritable bowel syn-
drome are excluded from the analysis. Quality of life is deﬁned
using the SF-8. The Work Productivity and Activity Impairment
(WPAI) scale is used to quantify productivity loss. Linear regres-
sion models are used to control for potential confounders includ-
ing demographics, number of physical comorbid conditions, and
experiencing psychiatric comorbid conditions. RESULTS: The
sample includes 1,288 (3%) chronic constipation sufferers and
35,676 (97%) non-sufferers. Chronic constipation sufferers
have signiﬁcantly worse mean physical (40.08 versus 48.79,
p < 0.001) and mental (42.13 versus 49.75, p < 0.001) quality of
life than non-sufferers. Controlling for potential confounders,
constipation sufferers have SF-8 physical summary scores that
are 3.550 (p < 0.001) points lower and SF-8 mental summary
scores that are 2.891 (p < 0.001) points lower than non-sufferers.
Among respondents employed full-time, chronic constipation
sufferers have signiﬁcantly greater productivity loss due to absen-
teeism (8.35 versus 3.10, p < 0.001), presenteeism (29.36 versus
13.36, p < 0.001), and overall (25.54 versus 12.18, p < 0.001).
Controlling for potential confounders, constipation sufferers
have greater absenteeism scores (3.102 points higher, p < 0.001),
presenteeism scores (7.782 points higher, p < 0.001), and overall
work productivity loss (6.017 points higher, p < 0.001) than
non-sufferers. Chronic constipation sufferers also experience
greater activity impairment (48.71 versus 21.75, p < 0.001) than
non-sufferers, and have activity impairment scores 11.708 higher
(p < 0.001) after controlling for potential confounders. CON-
CLUSION: Chronic constipation has signiﬁcant negative effects
on physical and mental quality of life, work productivity, and
activity impairment.
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OBJECTIVES: To obtain the multi-attribute utility function
(MAUF) for the Spanish version of the Short Form 6-D (SF-6D)
and to compare utilities values with those determined by the
British MAUF. To determine the weights of SF-36v1 items con-
forming the SF-6D instrument. METHODS: A whole-nation rep-
resentative sample of 2,549 subjects [48.9% men, 48.5 (14.01)
years] with mild to severe degree of Gastroesophageal Reﬂux
Disease was recruited by 500 clinicians selected at random and
used for this analysis. The Spanish versions of SF-6D and EQ-5D
questionnaires plus the corresponding visual analogue scale were
self-completed. Attribute weights were estimated using a cat-
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